modelTriazolam

Diagram of Triazolam

Extends from Pharmacolibrary.Drugs.ATC.N.N05CD05.

Information

name:Triazolam
ATC code:N05CD05
route:oral
compartments:2
dosage:0.5mg
volume of distribution:1.3L
clearance:1.5mL/min/kg
other parameters in model implementation

Triazolam is a short-acting benzodiazepine used primarily for the treatment of insomnia. It is indicated for short-term management of sleep disorders and is not recommended for long-term use due to dependence and tolerance risks. Triazolam is still available in some countries but its use is restricted or discontinued in others due to safety concerns.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers (male and female), age 19-38 years, after a single oral dose.

References

  1. Friedman, H, et al., & Shader, RI (1986). Population study of triazolam pharmacokinetics. British journal of clinical pharmacology 22(6) 639–642. DOI:10.1111/j.1365-2125.1986.tb02951.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/3567010

  2. Ozdemir, V, et al., & Naranjo, CA (1996). Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?. Clinical pharmacokinetics 31(5) 372–385. DOI:10.2165/00003088-199631050-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9118585

  3. Perucca, E, et al., & Fuseau, E (2008). Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 49(7) 1123–1141. DOI:10.1111/j.1528-1167.2008.01665.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/18503564

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)